Just months after the Supreme Court’s Dobbs decision, anti-abortion medical groups, including the Alliance for Hippocratic Medicine, launched a lawsuit seeking to overturn the FDA’s initial approval of mifepristone and its subsequent updates in 2016 and 2021 that expanded access to the medication. Their allegations include asserting the dangers of medication abortions, criticizing the FDA for allowing mifepristone’s approval, and arguing that the agency’s updates removed vital safeguards for women and girls.
Abortion Pill Battle : A Precarious Legal Battle Unfolds
The battle gained traction when U.S. District Judge Matthew J. Kacsmaryk granted an injunction favoring the anti-abortion litigants in early April, essentially halting all sales of mifepristone. This move was met with swift counteraction from Danco Laboratories, which, though not an initial party to the lawsuit, joined the federal government in appealing Judge Kacsmaryk’s ruling and obtained a partial stay from the Fifth Circuit. The Supreme Court then took the unprecedented step of staying all lower court decisions until the case could be fully reviewed.
